Innate Pharma: Capital and Voting Rights Update

On April 13, 2026, Innate Pharma disclosed the number of shares comprising its share capital as of April 9, 2026. Currently, the company has 93,860,680 shares, including 93,847,763 ordinary shares, 5,336 2016 Preference Shares, and 7,581 2017 Preference Shares. Regarding voting rights, the theoretical number is 94,484,443, while the exercisable voting rights are 94,465,868. This data is published in accordance with the regulations of the AMF (French Financial Markets Authority).

Innate Pharma, listed on Euronext Paris and Nasdaq, is active in the development of immunotherapy treatments for cancer. Based in Marseille, the company collaborates with biopharmaceutical giants such as Sanofi and AstraZeneca.